Pro Medicus (ASX:PME) has become one of the most remarkable success stories on the ASX: a Melbourne-based medical-imaging software company whose Visage platform is used by leading hospital networks across the United States to store, distribute and read radiology images. Its combination of very high margins, recurring transaction-based Revenue and marquee customer wins has driven an extraordinary re-rating over the past decade. The FY26 result, released on 18 August 2026, showed the growth engine still running hard — and raised the question of whether the company is entering a pivotal new phase of scale.

The appeal has always been the economics. Pro Medicus sells cloud-based software with minimal incremental cost, so each new contract flows heavily to profit. FY26 illustrated that Leverage vividly.

FY26 by the numbers

Revenue rose to AUD 261.7 million, or AUD 273.5 million on a constant-currency basis, representing underlying growth of about 28%. Underlying EBIT reached AUD 196.1 million, an eye-catching Margin of 74.9%, while underlying net profit after tax was AUD 144.7 million at a 55.3% margin. Reported net profit of AUD 265.3 million was flattered by large non-cash gains, so the underlying figure is the better guide to operating performance.

The Balance Sheet remains pristine: cash and financial Assets of AUD 252.3 million, no borrowings, and net tangible assets of AUD 4.10 per share. The board lifted the total fully Franked Dividend to 69.0 cents per share, up from 55.0 cents, comprising a 32.0-cent interim and 37.0-cent final payout.

Contract momentum

The more important metric for a Business like this is the forward book. Pro Medicus secured AUD 407 million in new contract wins during FY26, spanning 10 new agreements — nine in the US and one in Europe — plus six renewals worth AUD 141 million. Management said the forward contract pipeline reached about AUD 1.34 billion over five years, a 41.3% increase year-on-year. That Backlog underpins the recurring, transaction-linked revenue that gives the model its visibility and helps explain why FY27 could be even stronger.

Geographically, North America remains dominant at AUD 236.8 million of revenue, with Australia at AUD 19.0 million and Europe at AUD 5.9 million — highlighting both the US concentration and the early-stage European opportunity.

Why the phase looks pivotal

Several threads suggest an inflection. The contract book has grown faster than revenue, implying a runway of committed work still to be recognised. The company is expanding beyond core radiology into adjacencies such as cardiology and, increasingly, artificial-intelligence tools layered onto its imaging platform. And the European foothold offers a second major geography to complement US penetration. Investors will watch the cadence of new contract announcements, the ramp of recently signed deals, and progress on AI and adjacent modalities.

The valuation and risks

The central risk is not the business but its price. Pro Medicus trades on one of the richest valuations on the ASX, leaving little room for disappointment; any slowdown in contract wins or delay in deal ramp-ups could trigger sharp de-rating. Customer concentration in large US health systems, currency exposure given US-dollar revenue, competition from established imaging vendors, and the lumpiness of large contract timing are all genuine considerations. The reliance on non-cash items in the reported profit also warrants scrutiny.

On balance, FY26 confirmed a business compounding at a rare combination of high growth and extreme margins, with a rising contract backlog and a lifted dividend. The operational story is entering a larger, more diversified phase across geographies and modalities. For investors, the fundamentals are exceptional — but the demanding valuation means the margin for error is unusually thin, and the pace of future contract wins will be the key thing to watch.